Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11109
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChételat, Gaël-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorPike, Kerryn E-
dc.contributor.authorBaron, Jean-Claude-
dc.contributor.authorBourgeat, Pierrick-
dc.contributor.authorJones, Gareth-
dc.contributor.authorFaux, Noel G-
dc.contributor.authorEllis, Kathryn A-
dc.contributor.authorSalvado, Olivier-
dc.contributor.authorSzoeke, Cassandra-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorAmes, David-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorRowe, Christopher C-
dc.date.accessioned2015-05-16T00:41:48Z
dc.date.available2015-05-16T00:41:48Z
dc.date.issued2010-08-25-
dc.identifier.citationBrain : A Journal of Neurology 2010; 133(11): 3349-58en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11109en
dc.description.abstractβ-Amyloid deposition is one of the main hallmarks of Alzheimer's disease thought to eventually cause neuronal death. Post-mortem and neuroimaging studies have consistently reported cases with documented normal cognition despite high β-amyloid burden. It is of great interest to understand what differentiates these particular subjects from those without β-amyloid deposition or with both β-amyloid deposition and cognitive deficits, i.e. what allows these subjects to resist the damage of the pathological lesions. [¹¹C]Pittsburgh compound B positron emission tomography and magnetic resonance brain scans were obtained in 149 participants including healthy controls and patients with subjective cognitive impairment, mild cognitive impairment and Alzheimer's disease. Magnetic resonance data were compared between high versus low-[11C]Pittsburgh compound B cases, and between high-[¹¹C]Pittsburgh compound B cases with versus those without cognitive deficits. Larger temporal (including hippocampal) grey matter volume, associated with better episodic memory performance, was found in high- versus low-[¹¹C]Pittsburgh compound B healthy controls. The same finding was obtained using different [¹¹C]Pittsburgh compound B thresholds, correcting [¹¹C]Pittsburgh compound B data for partial averaging, using age, education, Mini-Mental State Examination, apolipoprotein E4 and sex-matched subsamples, and using manual hippocampal delineation instead of voxel-based analysis. By contrast, in participants with subjective cognitive impairment, significant grey matter atrophy was found in high-[¹¹C]Pittsburgh compound B cases compared to low-[¹¹C]Pittsburgh compound B cases, as well as in high-[¹¹C]Pittsburgh compound B cases with subjective cognitive impairment, mild cognitive impairment and Alzheimer's disease compared to high-[¹¹C]Pittsburgh compound B healthy controls. Larger grey matter volume in high-[¹¹C]Pittsburgh compound B healthy controls may reflect either a tissue reactive response to β-amyloid or a combination of higher 'brain reserve' and under-representation of subjects with standard/low temporal volume in the high-[¹¹C]Pittsburgh compound B healthy controls. Our complementary analyses tend to support the latter hypotheses. Overall, our findings suggest that the deleterious effects of β-amyloid on cognition may be delayed in those subjects with larger brain (temporal) volume.en
dc.language.isoenen
dc.subject.otherAge Factorsen
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAlzheimer Disease.metabolism.pathologyen
dc.subject.otherAmyloid beta-Peptides.metabolismen
dc.subject.otherApolipoproteins E.geneticsen
dc.subject.otherCohort Studiesen
dc.subject.otherFemaleen
dc.subject.otherHeterozygoteen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherOrgan Sizeen
dc.subject.otherTemporal Lobe.metabolism.pathologyen
dc.titleLarger temporal volume in elderly with high versus low beta-amyloid deposition.en
dc.typeJournal Articleen
dc.identifier.journaltitleBrainen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australiaen
dc.identifier.affiliationchetelat@cyceron.fren
dc.identifier.doi10.1093/brain/awq187en
dc.description.pages3349-58en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20739349en
dc.contributor.corpauthorAustralian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Groupen
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherMasters, Colin L
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.openairetypeJournal Article-
item.fulltextWith Fulltext-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
20739349.pdf467.42 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

46
checked on Nov 3, 2024

Download(s)

130
checked on Nov 3, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.